secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lipocine Inc. (LPCN)
CIK:        0001535955
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001493152-26-021638
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipocine misses Q1 EPS estimates; LPCN 1154 PPD Phase 3 fails primary endpoint
------------------------------------------------------------------------------

- Net loss of $3.7M ($0.52/share) vs $1.9M loss ($0.35) in Q1 2025; cash $24.7M.
- Phase 3 trial of LPCN 1154 for postpartum depression missed primary endpoint; HAM-D reduction vs placebo not significant at hour 60.
- LPCN 1154 well-tolerated; no serious AEs, sedation, or loss of consciousness; post hoc significance in patients with psychiatric history (n=54).
- Company applied for breakthrough/fast track designations for LPCN 1154; evaluating validation study or strategic options.
- TLANDO royalty revenue $119K in Q1 2026 versus $94K in prior year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/0001493152-26-021638-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1535955/000149315226021638/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-021638

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer